Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
<p>Abstract</p> <p>Background</p> <p>Androgen deprivation therapy (ADT) has been reported to reduce the bone mineral density (BMD) in men with prostate cancer (CaP). However, Afro-Caribbeans are under-represented in most studies. The aim was to determine the effect of a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2011-09-01
|
| Series: | Infectious Agents and Cancer |
| _version_ | 1818147792912121856 |
|---|---|
| author | Mayhew Richard G Aiken William D Burrowes Ingrid E Morrison Belinda F Fletcher Horace M Reid Marvin E |
| author_facet | Mayhew Richard G Aiken William D Burrowes Ingrid E Morrison Belinda F Fletcher Horace M Reid Marvin E |
| author_sort | Mayhew Richard G |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Androgen deprivation therapy (ADT) has been reported to reduce the bone mineral density (BMD) in men with prostate cancer (CaP). However, Afro-Caribbeans are under-represented in most studies. The aim was to determine the effect of androgen deprivation therapy (ADT) on the bone mineral density (BMD) of men with prostate cancer in Jamaica.</p> <p>Methods</p> <p>The study consisted of 346 Jamaican men, over 40 years of age: 133 ADT treated CaP cases (group 1), 43 hormone-naïve CaP controls (group 2) and 170 hormone naïve controls without CaP (group 3). Exclusion criteria included metastatic disease, bisphosphonate therapy or metabolic disease affecting BMD. BMD was measured with a calcaneal ultrasound and expressed in S.D. units relative to young adult men (T score), according to the World Health Organization definition. Patient weight, height and BMI were assessed.</p> <p>Results</p> <p>Mean ± sd, age of patients in group 1 (75± 7.4 yrs) was significantly greater than groups 2 and 3 (67 ± 8.1 yrs; 65±12.0 yrs). There was no significant difference in weight and BMI between the 3 groups. . The types of ADT (% of cases, median duration in months with IQR) included LHRH (Luteinizing hormone releasing hormone) analogues (28.6%, 17.9, IQR 20.4), oestrogens (9.8%, 60.5, IQR 45.6) anti-androgens (11.3%, 3.3, IQR 15.2) and orchiectomy (15.7%, 43.4, IQR 63.9). Unadjusted t score of group 1, mean ± sd, (-1.6± 1.5) was significantly less than group 2 (-0.9±1.1) and group 3 (-0.7±1.4), p <0.001. Ninety three (69.9%), 20 (45%) and 75 (42%) of patients in groups 1, 2 and 3 respectively were classified as either osteopenic or osteoporotic (p<0.001). Adjusting for age, there was a significant difference in t scores between groups 1 and 2 as well as between groups 1 and 3 (p<0.001). Compared with oestrogen therapy and adjusting for duration of therapy, the odds of low bone mineral density (osteopenia or osteoporosis) with LHRH analogue was 4.5 (95%CI, 14.3 to 3.4); with anti-androgens was 5.9 (95%CI, 32.7 to 5); with orchiectomy was 7.3 (95%CI, 30 to 5.8) and multiple drugs was 9.2 ((95%CI, 31 to 7.1).</p> <p>Conclusions</p> <p>ADT is associated with lower BMD in Jamaican men on hormonal therapy for prostate cancer.</p> |
| first_indexed | 2024-12-11T12:40:53Z |
| format | Article |
| id | doaj.art-e2cd7145e1f84acf93844e7460211107 |
| institution | Directory Open Access Journal |
| issn | 1750-9378 |
| language | English |
| last_indexed | 2024-12-11T12:40:53Z |
| publishDate | 2011-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Infectious Agents and Cancer |
| spelling | doaj.art-e2cd7145e1f84acf93844e74602111072022-12-22T01:06:59ZengBMCInfectious Agents and Cancer1750-93782011-09-016Suppl 2S710.1186/1750-9378-6-S2-S7Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancerMayhew Richard GAiken William DBurrowes Ingrid EMorrison Belinda FFletcher Horace MReid Marvin E<p>Abstract</p> <p>Background</p> <p>Androgen deprivation therapy (ADT) has been reported to reduce the bone mineral density (BMD) in men with prostate cancer (CaP). However, Afro-Caribbeans are under-represented in most studies. The aim was to determine the effect of androgen deprivation therapy (ADT) on the bone mineral density (BMD) of men with prostate cancer in Jamaica.</p> <p>Methods</p> <p>The study consisted of 346 Jamaican men, over 40 years of age: 133 ADT treated CaP cases (group 1), 43 hormone-naïve CaP controls (group 2) and 170 hormone naïve controls without CaP (group 3). Exclusion criteria included metastatic disease, bisphosphonate therapy or metabolic disease affecting BMD. BMD was measured with a calcaneal ultrasound and expressed in S.D. units relative to young adult men (T score), according to the World Health Organization definition. Patient weight, height and BMI were assessed.</p> <p>Results</p> <p>Mean ± sd, age of patients in group 1 (75± 7.4 yrs) was significantly greater than groups 2 and 3 (67 ± 8.1 yrs; 65±12.0 yrs). There was no significant difference in weight and BMI between the 3 groups. . The types of ADT (% of cases, median duration in months with IQR) included LHRH (Luteinizing hormone releasing hormone) analogues (28.6%, 17.9, IQR 20.4), oestrogens (9.8%, 60.5, IQR 45.6) anti-androgens (11.3%, 3.3, IQR 15.2) and orchiectomy (15.7%, 43.4, IQR 63.9). Unadjusted t score of group 1, mean ± sd, (-1.6± 1.5) was significantly less than group 2 (-0.9±1.1) and group 3 (-0.7±1.4), p <0.001. Ninety three (69.9%), 20 (45%) and 75 (42%) of patients in groups 1, 2 and 3 respectively were classified as either osteopenic or osteoporotic (p<0.001). Adjusting for age, there was a significant difference in t scores between groups 1 and 2 as well as between groups 1 and 3 (p<0.001). Compared with oestrogen therapy and adjusting for duration of therapy, the odds of low bone mineral density (osteopenia or osteoporosis) with LHRH analogue was 4.5 (95%CI, 14.3 to 3.4); with anti-androgens was 5.9 (95%CI, 32.7 to 5); with orchiectomy was 7.3 (95%CI, 30 to 5.8) and multiple drugs was 9.2 ((95%CI, 31 to 7.1).</p> <p>Conclusions</p> <p>ADT is associated with lower BMD in Jamaican men on hormonal therapy for prostate cancer.</p> |
| spellingShingle | Mayhew Richard G Aiken William D Burrowes Ingrid E Morrison Belinda F Fletcher Horace M Reid Marvin E Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer Infectious Agents and Cancer |
| title | Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer |
| title_full | Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer |
| title_fullStr | Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer |
| title_full_unstemmed | Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer |
| title_short | Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer |
| title_sort | bone mineral density in jamaican men on androgen deprivation therapy for prostate cancer |
| work_keys_str_mv | AT mayhewrichardg bonemineraldensityinjamaicanmenonandrogendeprivationtherapyforprostatecancer AT aikenwilliamd bonemineraldensityinjamaicanmenonandrogendeprivationtherapyforprostatecancer AT burrowesingride bonemineraldensityinjamaicanmenonandrogendeprivationtherapyforprostatecancer AT morrisonbelindaf bonemineraldensityinjamaicanmenonandrogendeprivationtherapyforprostatecancer AT fletcherhoracem bonemineraldensityinjamaicanmenonandrogendeprivationtherapyforprostatecancer AT reidmarvine bonemineraldensityinjamaicanmenonandrogendeprivationtherapyforprostatecancer |